Molecular description of ANGPT2 associated colorectal carcinoma.
Angiopoietin-2
/ blood
Clinical Trials as Topic
Colorectal Neoplasms
/ blood
Databases, Genetic
Drug Resistance, Neoplasm
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genetic Association Studies
Glycoproteins
/ blood
Humans
Male
Neoplasm Staging
Prognosis
Prospective Studies
Survival Analysis
Syndecan-1
/ blood
Stanniocalcin-1
Syndecan-1
angiopoietin-2
colorectal cancer
stroma
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
01
08
2019
revised:
01
02
2020
accepted:
26
02
2020
pubmed:
31
3
2020
medline:
10
4
2021
entrez:
31
3
2020
Statut:
ppublish
Résumé
Angiopoietin-2 (ANGPT2) is a prognostic factor in metastatic colorectal cancer (CRC). Nevertheless, it remains to be elucidated which molecular characteristics make up the ANGPT2-related poor-prognosis CRC subset. Public transcriptomic datasets were collected from Gene Expression Omnibus GEO and with the TCGAbiolinks R-package for the TCGA. After appropriate normalization, differential expression analysis was performed using Benjamini and Hochberg method for false discovery rate. Plasma from two prospective clinical trials were used to investigate the clinical impact of ANGPT2-related biomarkers. In the 935 samples included in four annotated platforms (GPL) and derived from localized CRC, ANGPT2
Substances chimiques
ANGPT2 protein, human
0
Angiopoietin-2
0
Glycoproteins
0
SDC1 protein, human
0
Syndecan-1
0
teleocalcin
76687-96-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2007-2018Informations de copyright
© 2020 UICC.
Références
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-6.
Lenz H-J, Ou F-S, Venook AP, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol 2019;37:1876-85.
Isella C, Brundu F, Bellomo SE, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun 2017;8:15107.
Pitroda SP, Khodarev NN, Huang L, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun 2018;9:1793.
Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 2017;8:86356-68.
Llovet JM, Peña CEA, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
Jary M, Vernerey D, Lecomte T, et al. Prognostic value of Angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 2015;24:603-12.
Reiss Y, Knedla A, Tal AO, et al. Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J Pathol 2009;217:571-80.
Gilles M-E, Maione F, Cossutta M, et al. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res 2016;76:7181-93.
Scott BB, Zaratin PF, Colombo A, et al. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002;29:230-9.
Fiedler U, Scharpfenecker M, Koidl S, et al. The tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
Coelho AL, Gomes MP, Catarino RJ, et al. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? Oncotarget 2016;8:39795-804.
Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
Seano G, Jain RK. Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis 2019;23:9-16.
Kuczynski EA, Vermeulen PB, Pezzella F, et al. Vessel co-option in cancer. Nat Rev Clin Oncol 2019;16:469-93.
Scholz A, Lang V, Henschler R, et al. Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin-dependent manner. Blood 2011;118:5050-9.
Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017;544:250-4.
Olar A, Goodman LD, Wani KM, et al. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget 2018;9:16087-98.
Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012;61:1560-7.
Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2010;29:17-24.
O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-44.
Masiero M, Simões FC, Han HD, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013;24:229-41.
Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (GEO) and BioConductor. Bioinformatics 2007;23:1846-7.
Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 2016;44:e71-1.
Kim S, Dobi E, Jary M, et al. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer 2013;13:611.
Tranquart F, Dujardin P-A, Bouché O, et al. Value of contrast-enhanced ultrasound quantification criteria for identifying patients not responding to Bevacizumab-based therapy for colorectal liver metastases. Ultraschall Med 2018;39:544-58.
Jary M, Lecomte T, Bouché O, et al. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score. Int J Cancer 2016;139:2325-35.
Olshen RA, Rajaratnam B. Successive standardization of rectangular arrays. Algorithms 2012;5:98-112.
Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016;17:218.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-50.
Volkova E, Willis JA, Wells JE, et al. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 2011;104:51-9.
Wei H, Wang F, Wang Y, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci 2017;108:478-87.
Colomb F, Wang W, Simpson D, et al. Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells. J Biol Chem 2017;292:8381-9.
Kan A, Le Y, Zhang Y-F, et al. ELTD1 function in hepatocellular carcinoma is carcinoma-associated fibroblast-dependent. J Cancer 2018;9:2415-27.
Torres S, Bartolomé RA, Mendes M, et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 2013;19:6006-19.
Calon A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320-9.
Peña C, Céspedes MV, Lindh MB, et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res 2013;73:1287-97.
Ohkouchi S, Ono M, Kobayashi M, et al. Myriad functions of Stanniocalcin-1 (STC1) cover multiple therapeutic targets in the complicated pathogenesis of idiopathic pulmonary fibrosis (IPF). Clin Med Insights Circ Respir Pulm Med 2015;9:91-6.
Coffelt SB, Tal AO, Scholz A, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010;70:5270-80.
Tabernero J, Lenz H-J, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48.
Azzariti A, Porcelli L, Brunetti O, et al. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016;22:6287-95.
Hacker UT, Escalona-Espinosa L, Consalvo N, et al. Evaluation of angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. Br J Cancer 2016;114:855-62.
Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75.
Bruno A, Mortara L, Baci D, et al. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol 2019;10:771.
Li H, Courtois ET, Sengupta D, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat Genet 2017;49:708-18.
di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape. Cancer Res 2011;71:19-28.
Griveau A, Seano G, Shelton SJ, et al. A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment. Cancer Cell 2018;33:874-889.e7.
Yadav VN, Zamler D, Baker GJ, et al. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: a genetic knockdown study. Oncotarget 2016;7:83701-19.
Wang Y, Qi Z, Zhou M, et al. Stanniocalcin-1 promotes cell proliferation, chemoresistance and metastasis in hypoxic gastric cancer cells via Bcl-2. Oncol Rep 2019;41:1998-2008.
Wang X, Zuo D, Chen Y, et al. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. Br J Cancer 2014;111:1965-76.
Li Y, He Z-C, Zhang X-N, et al. Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1. Cancer Lett 2018;416:66-74.
Sterzyńska K, Klejewski A, Wojtowicz K, et al. Mutual expression of ALDH1A1, LOX, and collagens in ovarian cancer cell lines as combined CSCs- and ECM-related models of drug resistance development. Int J Mol Sci 2018;20:54.
Ryner L, Guan Y, Firestein R, et al. Upregulation of Periostin and reactive Stroma is associated with primary Chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin Cancer Res 2015;21:2941-51.
Rossow L, Veitl S, Vorlová S, et al. LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy. Oncogene 2018;37:4921-40.